Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm

Inclusion Criteria: * Male or female adults aged between 12 and 60 years; * Written and signed informed consent; * Was examined by a study physician before treatment; * Provided two stool samples at baseline; * Hookworm EPG \> 48 and at least two Kato-Katz thick smears slides with more than one hookworm eggs. Exclusion Criteria: * Pregnant or lactating and/or planning to become pregnant within three months after drug treatment; * Type 1 and/or 2 diabetes; * Psychiatric disorders; * History of ophthalmological conditions; * Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment; * Suffers from severe anaemia (Hb \< 80 g/l); * Received anthelminthic treatment within past four weeks; * Attending other clinical trials during the study; * Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin; * Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir. * Participated in stage I trials of this protocol